AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36724067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with WST-11 at a dose of 200 mW/cm
Number of subjects: 19
Study 36724067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with WST-11
Number of subjects: 19
Study 36724109 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuranolone, dosage and duration not available
Number of subjects: 0
Study 36724181 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 111
Study 36724193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500mg twice daily for 8 weeks
Number of subjects: 180
Study 36724193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 180
Study 36724311 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual insulin pump (UP)
Number of subjects: 10
Study 36724311 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin delivery (AID) (MiniMed™ 780G)
Number of subjects: 10
Study 36724328 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 725
Study 36724328 — intervention group
Group type: COMPARATOR
Intervention: Ex situ kidney hypothermic machine perfusion
Number of subjects: 725
Study 36724328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (hypothermia + machine perfusion)
Number of subjects: 725
Study 36724328 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia vs Machine Perfusion
Number of subjects: 725
Study 36724328 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia vs Combination Therapy
Number of subjects: 725
Study 36724328 — intervention group
Group type: COMPARATOR
Intervention: Combination Therapy vs Machine Perfusion
Number of subjects: 725
Study 36724328 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft survival at 1 year
Number of subjects: 725
Study 36724328 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 725
Study 36724401 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived efficacy in patient-physician interaction
Number of subjects: 93
Study 36724401 — intervention group
Group type: COMPARATOR
Intervention: Low perceived efficacy in patient-physician interaction
Number of subjects: 93
Study 36724401 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch prescription for AF
Number of subjects: 93
Study 36724434 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dosed LPV/r (ratio 8:2)
Number of subjects: 16
Study 36724434 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisuperboosted LPV/r (adding a ritonavir 100 mg crushed tablet)
Number of subjects: 16
Study 36724434 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no rifampicin)
Number of subjects: 16
Study 36724434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin co-treatment
Number of subjects: 16
Study 36724515 — intervention group
Group type: EXPERIMENTAL
Intervention: Olutasidenib (FT-2102) 150 mg twice daily
Number of subjects: 153
Study 36724589 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Exercise (CE)
Number of subjects: 16
Study 36724589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IE)
Number of subjects: 16
Study 36724759 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF) at a convective rate of 5 µL/min with a maximum volume of infusion of 500 mL
Number of subjects: 4
Study 36724759 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF)
Number of subjects: 4
Study 36724791 — intervention group
Group type: EXPERIMENTAL
Intervention: Less baseline time in sedentary behavior (SB)
Number of subjects: 205
Study 36724939 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 360
Study 36724939 — intervention group
Group type: COMPARATOR
Intervention: MCV4-DT
Number of subjects: 360
Study 36725084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A)
Number of subjects: 589
Study 36725084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A1)
Number of subjects: 589
Study 36725084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (Cohorts A and A1)
Number of subjects: 589
Study 36725090 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED+antibiotics (azithromycin 7.5 mg/kg and metronidazole 20 mg/kg)
Number of subjects: 20
Study 36725090 — intervention group
Group type: COMPARATOR
Intervention: CDED+PEN alone
Number of subjects: 20
Study 36725090 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED+antibiotics
Number of subjects: 20
Study 36725099 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 595
Study 36725099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 595
Study 36725102 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media and smartphone use
Number of subjects: 600
Study 36725102 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, depression, sleep disturbance, loneliness, and bullying
Number of subjects: 600
Study 36725117 — intervention group
Group type: EXPERIMENTAL
Intervention: GPRC5D-targeted CAR T cells (OriCAR-017) administered as a single dose of intravenous 1 × 10^6 cells/kg
Number of subjects: 13
Study 36725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic White patients
Number of subjects: 21952
Study 36725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 21952
Study 36725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black patients
Number of subjects: 21952
Study 36725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Asian patients
Number of subjects: 21952
Study 36725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic other patients
Number of subjects: 21952
Study 36725171 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL system
Number of subjects: 98
Study 36725361 — intervention group
Group type: EXPERIMENTAL
Intervention: First Pass Effect (FPE)
Number of subjects: 279
Study 36725361 — intervention group
Group type: COMPARATOR
Intervention: Multiple Pass Effect (MPE)
Number of subjects: 279
Study 36725361 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Recanalization (ICR)
Number of subjects: 279
Study 36725431 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (heterologous booster)
Number of subjects: 305
Study 36725431 — intervention group
Group type: COMPARATOR
Intervention: BBIBP (homologous booster)
Number of subjects: 305
Study 36725433 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccination
Number of subjects: 32
Study 36725768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 166
Study 36725768 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 166
Study 36725836 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 0
Study 36726032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic diet (PD) adherence, characterized by high intake of fruit, vegetables, nuts, fish, and lean meat, and low intake of dairy, grains, legumes, refined sugar, and alcohol.
Number of subjects: 65574
Study 36726032 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic diet (PD) adherence (high adherence).
Number of subjects: 65574
Study 36726032 — intervention group
Group type: COMPARATOR
Intervention: Palaeolithic diet (PD) adherence (low adherence).
Number of subjects: 65574
Study 36726127 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation of reSET and reSET-O digital therapeutics for substance use disorder (SUD) including clinician training and electronic health record tools.
Number of subjects: 22
Study 36726127 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation and/or health coaching as added implementation strategies.
Number of subjects: 22
Study 36726127 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation of reSET and reSET-O digital therapeutics for SUD.
Number of subjects: 22
Study 36726148 — intervention group
Group type: EXPERIMENTAL
Intervention: X chromosome variant near TMSB4X, rs5979771
Number of subjects: 10193
Study 36726148 — intervention group
Group type: EXPERIMENTAL
Intervention: X chromosome genetic markers
Number of subjects: 10193
Study 36726148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in X chromosome variants
Number of subjects: 10193
Study 36726187 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, nurse-led follow-up with a focus on patient empowerment and use of electronic patient-reported outcome measures (ePROMs).
Number of subjects: 0
Study 36726187 — intervention group
Group type: COMPARATOR
Intervention: Standard, physician-led follow-up without use of ePROMs or specific focus on empowerment.
Number of subjects: 0
Study 36726191 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS-NSQIP
Number of subjects: 631
Study 36726191 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-adjusted ACS-NSQIP
Number of subjects: 631
Study 36726191 — intervention group
Group type: EXPERIMENTAL
Intervention: NELA
Number of subjects: 631
Study 36726191 — intervention group
Group type: EXPERIMENTAL
Intervention: P-POSSUM
Number of subjects: 631
Study 36726191 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Optimal Trees in Emergency Surgery Risk
Number of subjects: 631
Study 36726737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 10 mg
Number of subjects: 36
Study 36726737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 36
Study 36726737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 36
Study 36726737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (all doses)
Number of subjects: 36
Study 36726971 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR T cells (29 axi-cel, 24 tisa-cel)
Number of subjects: 53
Study 36726971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CAR-T systemic inflammation
Number of subjects: 53
Study 36727004 — intervention group
Group type: EXPERIMENTAL
Intervention: STS + Kangaroo care
Number of subjects: 0
Study 36727004 — intervention group
Group type: COMPARATOR
Intervention: Kangaroo care
Number of subjects: 0
Study 36727105 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment for 1 year
Number of subjects: 35
Study 36727222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib in combination with CAPEOX
Number of subjects: 0
Study 36727222 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab in combination with CAPEOX
Number of subjects: 0
Study 36727397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor therapy
Number of subjects: 112
Study 36727397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression predictive models
Number of subjects: 112
Study 36727397 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 20 pathways overexpressed in good responders
Number of subjects: 112
Study 36727470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab Monotherapy (n=111)
Number of subjects: 2541
Study 36727470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab + csDMARD (n=1910)
Number of subjects: 2541
Study 36727470 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation (n=165)
Number of subjects: 2541
Study 36727470 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch (n=155)
Number of subjects: 2541
Study 36727470 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 2541
Study 36727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus lobaplatin (EL) with concurrent thoracic radiotherapy
Number of subjects: 42
Study 36727741 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP) with concurrent thoracic radiotherapy
Number of subjects: 42
Study 36727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus lobaplatin (EL)
Number of subjects: 42
Study 36727741 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 42
Study 36727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EL and EP
Number of subjects: 42
Study 36727801 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy
Number of subjects: 57
Study 36727855 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl administration
Number of subjects: 72
Study 36727855 — intervention group
Group type: COMPARATOR
Intervention: Routine care (fentanyl given per clinical routine)
Number of subjects: 72
Study 36727866 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-P16-093 PET/CT
Number of subjects: 30
Study 36727868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch (1 mg)
Number of subjects: 188
Study 36727868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 36728001 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygenation target (Sp o2 > 94%)
Number of subjects: 75
Study 36728001 — intervention group
Group type: COMPARATOR
Intervention: Conservative oxygenation target (Sp o2 88-92%)
Number of subjects: 75
Study 36728126 — intervention group
Group type: EXPERIMENTAL
Intervention: AI software tool for CI programming
Number of subjects: 47
Study 36728139 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-PSMA PET/CT
Number of subjects: 1
Study 36728139 — intervention group
Group type: COMPARATOR
Intervention: 18 F-fluciclovine PET/CT
Number of subjects: 1
Study 36728194 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support at 3 months
Number of subjects: 161
Study 36728194 — intervention group
Group type: COMPARATOR
Intervention: Any therapy
Number of subjects: 161
Study 36728214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) for 4 years
Number of subjects: 201
Study 36728214 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF withdrawal
Number of subjects: 201
Study 36728217 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF)
Number of subjects: 73
Study 36728233 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study 36728233 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 0
Study 36728302 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) using the OrganOx metra device for a minimum of 4 hours.
Number of subjects: 22
Study 36728303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ICG (0.05 mg)
Number of subjects: 55
Study 36728303 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ICG (2.5 mg)
Number of subjects: 55
Study 36728375 — intervention group
Group type: EXPERIMENTAL
Intervention: ciNPT (Prevena Incision Management System, 3M Health Care)
Number of subjects: 144
Study 36728375 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound care
Number of subjects: 144
Study 36728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at <12 h
Number of subjects: 59447
Study 36728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at 12 to 24 h
Number of subjects: 59447
Study 36728532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive strategy
Number of subjects: 59447
Study 36728532 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis alone
Number of subjects: 59447
Study 36728573 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample strategy (T0 + T6)
Number of subjects: 77
Study 36728573 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample strategy (T0 + T1)
Number of subjects: 77
Study 36728573 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sample strategy (T6 only)
Number of subjects: 77
Study 36728573 — intervention group
Group type: COMPARATOR
Intervention: Three-sample strategy (T0, T1, T6)
Number of subjects: 77
Study 36728649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusfertide (hepcidin mimetic)
Number of subjects: 0
Study 36728649 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36728653 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline solution nasal spray (VNS) 0.03 mg
Number of subjects: 602
Study 36728848 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 120
Study 36728848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 120
Study 36728848 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 120
Study 36728848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36728874 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly intravitreal aflibercept injections (IAI) 2 mg
Number of subjects: 22
Study 36728954 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, nurse-directed sedation strategy
Number of subjects: 102
Study 36728954 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study 36728974 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily physical activity (PA)
Number of subjects: 124
Study 36728974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 124
Study 36728974 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting physical activity recommendations
Number of subjects: 124
Study 36728974 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means clustering based on percent of time spent in MVPA and ST
Number of subjects: 124
Study 36729084 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed (PRN) ranibizumab therapy
Number of subjects: 222
Study 36729239 — intervention group
Group type: EXPERIMENTAL
Intervention: Current caregivers
Number of subjects: 46
Study 36729239 — intervention group
Group type: COMPARATOR
Intervention: Former caregivers
Number of subjects: 46
Study 36729308 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 80
Study 36729308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 80
Study 36729308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 36729422 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 therapy for naïve CD patients
Number of subjects: 126
Study 36729422 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 therapy for switched CD patients
Number of subjects: 126
Study 36729422 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 therapy for all groups
Number of subjects: 126
Study 36729422 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 therapy for naïve UC patients
Number of subjects: 126
Study 36729422 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 therapy for switched UC patients
Number of subjects: 126
Study 36729441 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Number of subjects: 46
Study 36729441 — intervention group
Group type: COMPARATOR
Intervention: Warm compresses and eyelid massages
Number of subjects: 46
Study 36729473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, topical, and/or adjuvant agents for neuropathic mechanisms
Number of subjects: 0
Study 36729494 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-informed personalized treatment
Number of subjects: 79
Study 36729506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME) with a multitask deep learning network (MTN) for automated diagnosis of AIN 2+
Number of subjects: 77
Study 36729506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME)
Number of subjects: 77
Study 36729506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME) combined with HRA
Number of subjects: 77
Study 36729514 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 23
Study 36729514 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O
Number of subjects: 23
Study 36729514 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 23
Study 36729538 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised HIV Care Coordination Program (CCP)
Number of subjects: 960
Study 36729538 — intervention group
Group type: COMPARATOR
Intervention: Original HIV Care Coordination Program (CCP)
Number of subjects: 960
Study 36729552 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS intervention (early supported discharge)
Number of subjects: 2262
Study 36729552 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2262
Study 36729552 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 2262
Study 36729587 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation during general anesthesia with propofol.
Number of subjects: 30
Study 36729587 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation with varying propofol concentrations.
Number of subjects: 30
Study 36729587 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of 4 different offline machine learning algorithms.
Number of subjects: 30
Study 36729610 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer retinal tubulation (ORT) present
Number of subjects: 42
Study 36729711 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention (one-off)
Number of subjects: 0
Study 36729711 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention (annual)
Number of subjects: 0
Study 36729711 — intervention group
Group type: COMPARATOR
Intervention: Control scenario (no crowdsourcing)
Number of subjects: 0
Study 36729811 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D TSE T1-WI
Number of subjects: 158
Study 36729811 — intervention group
Group type: COMPARATOR
Intervention: 3D GRE T1-WI
Number of subjects: 158
Study 36729896 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGN@L-A (serious game with playful elements)
Number of subjects: 28
Study 36729896 — intervention group
Group type: COMPARATOR
Intervention: SIGN@L-B (serious game with only objectives and feedback)
Number of subjects: 28